Stockscreener 앱 받기
1.46
11.88%
0.155
시간 외 거래:
1.41
-0.05
-3.42%
Alx Oncology Holdings Inc 주식(ALXO)의 최신 뉴스
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update - MarketBeat
ALX Oncology (NASDAQ:ALXO) Price Target Lowered to $2.20 at UBS Group - Defense World
H.C. Wainwright cuts ALX Oncology target to $5, keeps buy rating - MSN
UBS cuts ALX Oncology target to $2.20, keeps Buy rating By Investing.com - Investing.com UK
ALX Oncology (NASDAQ:ALXO) Price Target Cut to $2.20 by Analysts at UBS Group - MarketBeat
Analysts Issue Forecasts for ALX Oncology FY2029 Earnings - MarketBeat
HC Wainwright Comments on ALX Oncology FY2029 Earnings - Defense World
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
HC Wainwright Has Lowered Expectations for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALX Oncology (NASDAQ:ALXO) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
ALX Oncology says evorpacept scores well in Phase II study - The Pharma Letter
Stifel maintains hold on ALX Oncology shares, keeps $3 target By Investing.com - Investing.com UK
ALX Oncology (NASDAQ:ALXO) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
Barclays PLC Grows Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Presents Positive Updated Data from ASPEN-06 - GlobeNewswire
Cantor Fitzgerald Forecasts ALX Oncology FY2025 Earnings - MarketBeat
Cantor Fitzgerald Predicts ALX Oncology FY2025 Earnings - Defense World
Evorpacept shows promise in HER2-positive cancer trial By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ALX Oncology Shares Drop 15% Following Positive Phase 2 - GuruFocus.com
ALX Oncology stock falls 16% amid Phase 2 data update - MSN
Cantor Fitzgerald Weighs in on ALX Oncology FY2025 Earnings - MarketBeat
Evorpacept shows promise in HER2-positive cancer trial - Investing.com India
ALX Oncology Holdings Inc. Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer - Marketscreener.com
ALX Oncology (ALXO) Presents Positive Updated Data from ASPEN-06 Phase 2 Trial - StreetInsider.com
ALX Oncology's Evorpacept Shows Breakthrough 49% Response Rate in Gastric Cancer Trial - StockTitan
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
ALX Oncology Grants 600,000 Stock Options to New CFO Harish Shantharam at $1.65 - StockTitan
ALX Oncology Announces Further Additions to Leadership Team - GlobeNewswire
ALX Oncology Strengthens Leadership with Key Appointments - TipRanks
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - The Manila Times
ALX Oncology Strengthens Leadership with Strategic CFO and Board Appointments for Clinical Push - StockTitan
ALX Oncology to Host Virtual Company Event Highlighting - GlobeNewswire
ALX Oncology to Present Crucial Evorpacept Cancer Trial Data at ASCO GI Symposium - StockTitan
ALX Oncology launches new equity incentive plan - MSN
ALX Oncology launches new equity incentive plan By Investing.com - Investing.com South Africa
ALX Oncology Adopts 2025 Inducement Equity Plan - TipRanks
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in December - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jane Street Group LLC Trims Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Barclays PLC Buys 42,185 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
State Street Corp Trims Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
3.95%
2.39%
자본화:
|
볼륨(24시간):